Tekmira Pharmaceuticals Extends Research Collaboration With Bristol-Myers Squibb Through 2009

Tekmira Pharmaceuticals announced today that Bristol-Myers Squibb Company has exercised an option to extend through 2009 the research collaboration between the two companies

VANCOUVER, BRITISH COLUMBIA, CANADA | March 25, 2009 | Tekmira Pharmaceuticals Corporation (TSX: TKM.TO) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has exercised an option to extend through 2009 the research collaboration between the two companies.

The collaboration focuses on validating certain gene targets using small interfering RNA (siRNA) provided by Bristol-Myers Squibb and employing Tekmira's stable nucleic-acid lipid particle (SNALP) formulations to deliver the siRNA.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "Our continuing relationship with Bristol-Myers Squibb exemplifies our strategy of collaborating with the world's leading pharmaceutical companies to expand the potential applications of our SNALP technology. These collaborations also complement our internal product development programs as we advance our own proprietary RNAi therapeutics to treat serious human diseases."

About RNAi and SNALP

RNAi drugs have the potential to treat human diseases by "switching-off" disease causing genes. The technology was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi drugs, such as siRNA, require delivery technology to be administered systemically. In preclinical studies, Tekmira's SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites. Tekmira believes it has a leading intellectual property position in the field of siRNA delivery.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

SOURCE: Tekmira Pharmaceuticals Corporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up